Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

Clinical and Experimental Medicine

Volumn 6, Issue 4, 2006, Pages 191-193

  Jinnouchi, Y ^a,d   Yamagishi, S ^a   Takeuchi, M ^b   Ishida, S ^c   Jinnouchi, J ^d   Imaizumi, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c Ishida Clinic   (Japan)

^d Sasaguri Hospital   (Japan)

Author keywords

AGEs; Diabetes; Oxidative stress; Statin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL; DIET THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MATCHED-PAIR ANALYSIS; PYRROLES;

EID: 33845867950     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-006-0115-6     Document Type: Letter

References (8)

1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685-696
2. Ray KK, Cannon CP (2005) Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother 6:915-927
3. West of Scotland Coronary Prevention Study Group (1998) Influence of pravastatin and plasma lipids on chemical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445
4. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299
5. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238
6. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y (2000) Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6:114-125
7. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790
8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138:271-280